New Disease Progression Study Findings Has Been Reported by a Researcher at Washington University (Improve Statistical Efficacy Inference: Global Reduction Rate in Disease Progression).

Researchers at Washington University have proposed a new statistical method, the Global Reduction Rate (GRR), to evaluate treatment efficacy in disease progression, specifically in Alzheimer's disease trials. The GRR is calculated by modeling the percentage reduction in disease progression across multiple endpoints, showing power advantages compared to traditional statistical methods. This method offers greater interpretability and does not require additional assumptions, making it a valuable tool in evaluating treatment effects. The study was published in Alzheimer's & Dementia and can be accessed for free online. [Extracted from the article]